The American Journal of Medicine
Volume 120, Issue 1 , Pages 1-4 , January 2007

Aspirin Resistance: Is it Real? Is it Clinically Significant?

References 

  1. Antithrombotic Trialists’Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  2. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S–63S
  3. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin Resistance: position paper of the working group on aspirin resistance. J Thromb and Hemostasis. 2005;3:1309–1311
  4. Chen W, Lee P, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43:1122–1126
  5. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110:489–493
  6. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655
  7. Maree AO, Curtin RJ, Dooley M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005;47:1258–1263
  8. Steinhubl SR, Charnigo R, Moliterno DJ. Resistance to antiplatelet resistance. J Am Coll Cardiol. 2005;45:1757–1758
  9. Topol EJ, Gum P, Kottke-Marchant K. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease (Reply). J Am Coll Cardiol. 2003;42:1336–1337
  10. Craft RM, Chavez JJ, Bresee SJ, et al. A novel modification of the thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med. 2004;143:301–309
  11. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46:1705–1709
  12. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002;107:45–49
  13. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol. 2002;9:407–415
  14. Hart RG, Leonard AD, Talbert RL, et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacother. 2003;23:579–584
  15. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol. 2005;46:986–993
  16. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay. Circulation. 1999;99:620–625
  17. Malinin AI, Atar D, Callahan KP, et al. Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur J Pharmacol. 2003;462:139–143
  18. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383
  19. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006;27:647–654
  20. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230–235
  21. Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin non responsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol. 2003;92:1492–1494
  22. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003;250:63–66
  23. Andersen K, Hurlen M, Arnesen H, et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2003;108:37–42
  24. Malinin A, Spergling M, Muhlestein B, et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis. 2004;15:295–301
  25. Lee P, Chen W, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005;118:723–727
  26. Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005;95:973–975
  27. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–965
  28. Dalen JE. Aspirin to prevent heart attack and stroke: what’s the right dose?. Am J Med. 2006;119:198–202
  29. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J. 2004;147:293–300
  30. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol. 2004;43:1127–1129
  31. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin?. Circulation. 2002;105:1620–1622
  32. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non-responder (A pilot-study including 180 post-stroke patients). Thromb Res. 1993;71:397–403
  33. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med. 2000;342:145–153

PII: S0002-9343(06)01070-9

doi: 10.1016/j.amjmed.2006.08.023

The American Journal of Medicine
Volume 120, Issue 1 , Pages 1-4 , January 2007

Article Tools